FDA's Priority Review of Addyi® Offers Hope for Postmenopausal Women's Sexual Health The FDA has granted Priority Review to Addyi®, a treatment for low sexual desire in postmenopausal women, paving the way for increased access and awareness.

FDA's Priority Review of Addyi® Offers Hope for Postmenopausal Women's Sexual Health #United_States #Raleigh #Sprout_Pharmaceuticals #Addyi #flibanserin

More Complicated Than 'Pink Viagra': What You Should Know... If you are a woman suffering from low sexual desire, woul...

#Flibanserin is not “female Viagra” (latter does not treat “desire”) and it has negligible benefits, lots of risks
http://onforb.es/1F02Fue